Open AccessDecision Analysis of Transplantation for Patients with Myelodysplasia: “Who Should We Transplant Today?”
Author(s) -
Shukaib Arslan,
Ryotaro Nakamura
Publication year - 2020
Publication title -
current hematologic malignancy reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.299
H-Index - 35
eISSN - 1558-822X
pISSN - 1558-8211
DOI - 10.1007/s11899-020-00573-6
Subject(s) - medicine , myelodysplastic syndromes , hematology , transplantation , oncology , natural history , azacitidine , international prognostic scoring system , hematopoietic stem cell transplantation , disease , intensive care medicine , bone marrow , dna methylation , biochemistry , gene expression , chemistry , gene
Myelodysplastic syndrome (MDS) is a heterogeneous hematological disorder characterized by a spectrum of clinical presentation, cytogenetic, and somatic gene mutations and the risk of transformation to acute leukemia. Management options include observation, supportive care, blood transfusion, administration of growth factors and/or hypomethylating agents, and hematopoietic cell transplant (HCT) either upfront or after disease progression.